Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
e-Consulting (Spanish version)
Nanda, Ashish; DeLong, Thomas J.; Landry, Scot; Agan, Thomas E.Caso HBS-804S07Servicios y operacionesProporciona una visión general de la historia y el desarrollo de la industria del e-consulta, así como las cuestiones que se le plantean.Desde 8,20 €
-
Erik Peterson at Biometra (E)
Gabarro, John J.; DeLong, Thomas J.; Soo, JevanCaso HBS-411035-ELiderazgo y Dirección de personasPresents the final outcome of the events. The Richard Jenkins at SciMat case presents a description from the executive vice-president's point of view of the series of events as reported in the Erik Peterson at Biometra (A), (B), (C), and (D) cases. The Jenkins at SciMat case can be assigned with Erik Peterson at Biometra (E) to give a broader perspective on Peterson's behavior and problems. This case can be handed out during class discussion of t...Desde 5,74 €
-
General Electric, 1984 (Spanish Version)
Aguilar, Francis J.; Hamermesh, Richard G.; Brainard, Caroline E.Caso HBS-302S36Conocimiento y comunicaciónDescribe los primeros cuatro años de permanencia de Jack Welch como CEO de las ofertas de General Electric Co. con las formas Welch ha tratado de actividades de estrategia y planificación del cambio de GE y sus intentos de hacer la empresa más empresarial.Desde 8,20 €
-
Busyness: The First of the Higher Powers--How to Free Yourself from Mundane, Repetitious Tasks and Open Yourself to New Challenges
DeLong, Thomas J.Capítulo de Libro HBS-8524BC-ERacing from one meeting to the next? Spending every free moment answering e-mails? Never getting any "real" work done? In this chapter, organizational behavior expert Thomas DeLong introduces the first of four traps that keep achievement-craving individuals from realizing their full potential: busyness. Of course you have a lot to do--and some of it is challenging, meaningful work. But if you find yourself stuck doing mundane, repetitious tasks o...Desde 8,20 €
-
Bloodbuy
Hamermesh, Richard G.; Norris, MichaelCaso HBS-815114-EIniciativa emprendedoraIn 2015, Chris Godfrey, founder and CEO of Bloodbuy has to consider the best path to growth for his young company that is attempting to disrupt the blood donation industry.Desde 8,20 €
-
Amylin Pharmaceuticals B
Hamermesh, Richard G.; Knoop, Carin-IsabelCaso HBS-813091-EIniciativa emprendedoraSupplement for case 809011Desde 8,20 €
-
Novasys Medical
Hamermesh, Richard G.; Barley, LaurenCaso HBS-810027-EIniciativa emprendedoraNovasys has developed a new medical device and procedure for the treatment of female stress urinary incontinence that is cheaper and can be performed in doctors' offices. In spite of FDA approval, the American Medical Association has been unwilling to approve the product for reimbursement. The case deals with the company's struggle to obtain a reimbursement code.Desde 8,20 €
-
Impact Investing for Cancer
Hamermesh, Richard G.; Preble, MatthewCaso HBS-818068-EDirección estratégicaDesde 8,20 €
-
Medalogix
Hamermesh, Richard G.; Preble, MatthewCaso HBS-815116-EIniciativa emprendedoraThis case examines an exciting new approach to health care that will help care providers identify when hospice services are the appropriate type of care for patients. The company, Medalogix, already has a product on the market that uses a proprietery algorithm to consider dozens of factors and determine when a patient qualifies for a hospice care eligability review. The product has started to gain traction, and the case explores how Medalogix can...Desde 8,20 €
-
Gene Patents (A)
Hamermesh, Richard G.; Kiron, David; Andrews, PhillipCaso HBS-811089-EIniciativa emprendedoraIn March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our increasing knowledge of the Human Genome. The case issues deal with the potential implications of Judge Sweet's decision for biotechnology entrepreneurs and investors.Desde 8,20 €